Both companies' stocks were down less than 1% on Thursday after reporting earnings before the bell. watch nowRoche forecast 2026 profit growth to outpace sales growth and for adjusted earnings per share to grow by high single digits at constant currencies, the same outlook it issued for 2025. "Growth was supported by new medicines and Dupixent, reaching a new quarterly high," CEO Paul Hudson said in a statement. Similar to Roche, Sanofi also sees sales growing by high-single digits in 2026, with profit growth "slightly higher than revenue." Despite the beat and a newly announced 1 billion euro share buyback, the focus for Sanofi investors remains on the company's research and development.